Articles

Vantage logo

Lilly spends big on mirikizumab

With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.

Vantage logo

Zogenix hands GW a win

A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.

Vantage logo

Big-caps join the coronavirus scramble

It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.